Clinical Report: ELARA Data Support Monthly Aflibercept 8 mg in Refractory nAMD and DME
Overview
The ELARA study demonstrates that monthly dosing of aflibercept 8 mg leads to significant visual acuity and central retinal thickness improvements in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) who have been previously treated with anti-VEGF agents. The safety profile aligns with previous pivotal trials.
Background
Aflibercept 8 mg (Eylea HD) has been introduced as a treatment option for patients with nAMD and DME, conditions that can lead to severe vision loss. Understanding its efficacy and safety in previously treated patients is crucial for optimizing treatment strategies in this challenging patient population.
Data Highlights
No numerical data provided in the source material.
Key Findings
- Monthly aflibercept 8 mg dosing showed visual acuity benefits in both nAMD and DME patients.
- Central retinal thickness improvements were observed in the study population.
- The safety data for aflibercept 8 mg is consistent with findings from pivotal trials.
- The updated label allows for the use of aflibercept 8 mg in hard-to-treat patients.
- ELARA findings support the use of aflibercept 8 mg in patients previously treated with anti-VEGF agents.
Clinical Implications
The findings from the ELARA study provide evidence for the use of aflibercept 8 mg in patients with nAMD and DME who have not responded adequately to prior treatments. Clinicians may consider this option for managing difficult cases.
Conclusion
The ELARA study reinforces the potential of aflibercept 8 mg as a viable treatment option for refractory cases of nAMD and DME, with promising visual and anatomical outcomes.
Related Resources & Content
- Dhoot, D.S., Retinal Physician, 2026 -- ELARA Data Support Monthly Aflibercept 8 mg in Refractory nAMD and DME
- Do, D.V., Retinal Physician, 2025 -- ELARA 24-Week Data Show Improvements in Wet AMD and DME
- Chaudhry, N.A., Retinal Physician, 2026 -- ELARA Tests Eylea HD Durability
- American Academy of Ophthalmology, 2025 -- Age-Related Macular Degeneration Preferred Practice Pattern®
- retinal physician — Real-World Eylea HD Data Presented at ARVO
- Retinal Physician — SUBSPECIALTY NEWS
- Age-Related Macular Degeneration Preferred Practice Pattern® - Ophthalmology
- Clinical Review - Aflibercept 8 mg (0.07 mL) (Eylea HD) - NCBI Bookshelf
- https://congresspublications.bayer.com/download/RGN_NEW_ANGIOGENESIS_2026_ELARA_24-week_PRIMARY_RESULTS_BROWN_VIRTUAL_PRESENTATION_09FEB.pdf
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
